Snehal Shah

Dr. Snehal Shah is Senior Vice President, Chief Regulatory Affairs and Pharmacovigilance Officer at Iveric Bio. Dr. Shah brings over 16 years of global experience in Regulatory Science and Pharmacovigilance, gained at leading pharmaceutical companies including Hoffmann La-Roche/ Genentech, Noven Pharmaceuticals (Member of the Hisamitsu Group) and Kyowa Kirin.

Dr. Shah has led both biologics and small molecule development programs focusing on rare orphan diseases, oncology, neurology, virology, transplantation, inflammation, endocrinology, and women’s health; at all product lifecycle phases through commercialization. Most notably Dr. Shah has provided strategic Regulatory leadership to successfully bring over a dozen market applications from filing through approval, allowing new treatment options for patients. This includes first in class treatments for rheumatoid arthritis, vasomotor symptoms associated with menopause, cutaneous T-cell lymphoma, and Parkinson's disease.

Dr. Shah holds a B.S. in pharmacy from Rutgers University and a Doctorate of Pharmacy from the University of Kansas. He also completed the American Course of Drug Development and Regulatory Sciences Certification program at the University of California, San Francisco.